CA2550302C - L-(-)-moprolol l-(+)-tartrate - Google Patents

L-(-)-moprolol l-(+)-tartrate Download PDF

Info

Publication number
CA2550302C
CA2550302C CA2550302A CA2550302A CA2550302C CA 2550302 C CA2550302 C CA 2550302C CA 2550302 A CA2550302 A CA 2550302A CA 2550302 A CA2550302 A CA 2550302A CA 2550302 C CA2550302 C CA 2550302C
Authority
CA
Canada
Prior art keywords
moprolol
tartrate
pharmaceutical composition
salt
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2550302A
Other languages
English (en)
French (fr)
Other versions
CA2550302A1 (en
Inventor
Mario Pinza
Caterina Maugeri
Nicola Cazzolla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CA2550302A1 publication Critical patent/CA2550302A1/en
Application granted granted Critical
Publication of CA2550302C publication Critical patent/CA2550302C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Detergent Compositions (AREA)
CA2550302A 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate Expired - Fee Related CA2550302C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2004A000145 2004-01-30
IT000145A ITMI20040145A1 (it) 2004-01-30 2004-01-30 L-moprololo lpiu' tartrato
PCT/EP2005/000560 WO2005075408A1 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Publications (2)

Publication Number Publication Date
CA2550302A1 CA2550302A1 (en) 2005-08-18
CA2550302C true CA2550302C (en) 2012-04-24

Family

ID=34835572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2550302A Expired - Fee Related CA2550302C (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Country Status (19)

Country Link
US (1) US7524886B2 (de)
EP (1) EP1708987B1 (de)
JP (1) JP4646922B2 (de)
KR (1) KR101122173B1 (de)
CN (1) CN100480232C (de)
AT (1) ATE502003T1 (de)
AU (1) AU2005211458B2 (de)
BR (1) BRPI0507150A (de)
CA (1) CA2550302C (de)
DE (1) DE602005026908D1 (de)
DK (1) DK1708987T3 (de)
EA (1) EA200601402A1 (de)
ES (1) ES2361518T3 (de)
IL (1) IL176280A (de)
IT (1) ITMI20040145A1 (de)
PL (1) PL1708987T3 (de)
PT (1) PT1708987E (de)
SI (1) SI1708987T1 (de)
WO (1) WO2005075408A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1211589A (en) * 1968-08-06 1970-11-11 Ici Ltd Enantiomer isolation process
IT1113029B (it) * 1979-03-01 1986-01-20 Simes Processo per la separazione dei due isomeri ottici del moprololo e composizioni farmaceutiche dell'antipodo levogiro
IT1163107B (it) * 1983-02-15 1987-04-08 Simes Composizioni farmaceutiche e loro uso nel trattamento del glaucoma
DE3544172A1 (de) * 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos

Also Published As

Publication number Publication date
CN1910138A (zh) 2007-02-07
US7524886B2 (en) 2009-04-28
KR20070000451A (ko) 2007-01-02
DK1708987T3 (da) 2011-06-27
CA2550302A1 (en) 2005-08-18
DE602005026908D1 (de) 2011-04-28
AU2005211458B2 (en) 2010-06-24
ATE502003T1 (de) 2011-04-15
HK1093962A1 (en) 2007-03-16
CN100480232C (zh) 2009-04-22
ES2361518T3 (es) 2011-06-17
PL1708987T3 (pl) 2011-08-31
EP1708987B1 (de) 2011-03-16
IL176280A (en) 2010-12-30
PT1708987E (pt) 2011-05-31
EA200601402A1 (ru) 2006-12-29
AU2005211458A1 (en) 2005-08-18
US20080015258A1 (en) 2008-01-17
KR101122173B1 (ko) 2012-03-15
JP2007519661A (ja) 2007-07-19
BRPI0507150A (pt) 2007-06-26
WO2005075408A1 (en) 2005-08-18
EP1708987A1 (de) 2006-10-11
IL176280A0 (en) 2006-10-05
JP4646922B2 (ja) 2011-03-09
ITMI20040145A1 (it) 2004-04-30
SI1708987T1 (sl) 2011-06-30

Similar Documents

Publication Publication Date Title
EP1480970B1 (de) Chinolinderivate
WO2021031999A1 (zh) 麦考酚酸的前体药物及其制备方法
US7524886B2 (en) L-(−)-moprolol L-(+)-tartrate
CA2551411C (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
HK1093962B (en) L-(-)-moprolol l-(+)-tartrate
MXPA06008528A (en) L-(-)-moprolol l-(+)-tartrate
EP0641563A1 (de) Arzneimittel gegen katarakt und seine herstellung
MXPA06008531A (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
KR20060136421A (ko) L-(-)-모프롤롤 l-(+)-타르타르산염
HK1093721B (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
EP0621779B1 (de) Indomethacin-lysinat zur therapeutischen verwendung in der ophthalmologie
EP1200079A2 (de) 2-aminotetraline zur behandlung von glaukom
EP1757601B1 (de) Chinolinderivate und ihre Anwendung bei Glaukom und Kurzsichtigkeit
HK1071364B (en) Quinoline derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190114